Inbrija (Levodopa) Patent Expiration, LOE Window & CMS Spending
Inbrija (Levodopa) by Merz: FDA Orange Book LOE 2033-10-21, 0 AB generics, $29.1M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Merz |
| FDA Application & Pathway | N209184 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2033-10-21 |
| Orange Book Patents (*PED Extensions) | 6 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $29.1M |
| 2024 Medicare Part D Spend | $27.7M |
| 2024 Medicaid Spend | $1.4M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 22.4% 2-yr change) |